Alterola Biotech INC

Alterola Biotech will restate its Q2 2024 financial statements due to an error in the consolidation of its subsidiaries, though the company believes the impact is not material.

Alterola Biotech has entered into a convertible promissory note agreement for $310,000 to bolster its working capital.

Alterola Biotech's Q2 2024 financial results reveal a significant increase in operating expenses and net loss as the company continues its strategic shift towards cannabinoid-based pharmaceuticals and prepares for a potential merger.

Alterola Biotech has filed an amended quarterly report to restate its financials for the period ended June 30, 2024, due to an error in consolidating its newly formed subsidiary, Phytanix Bio.

Alterola Biotech, a pharmaceutical company, released its unaudited financial results for the quarter ended June 30, 2024, alongside announcing a business combination agreement with Chain Bridge I.

Alterola Biotech's Q3 2023 report reveals continued operating losses, a significant working capital deficit, and material weaknesses in internal controls, raising concerns about the company's ability to continue as a going concern.

Alterola Biotech's Q3 2023 report reveals increased operating expenses and a larger net loss compared to the same period in 2022, alongside ongoing concerns about the company's ability to continue as a going concern.

Alterola Biotech's annual report reveals ongoing financial challenges and a lack of revenue, while highlighting its focus on cannabinoid-based pharmaceutical development.